Fig. 2: Overall (OS) of the entire cohort.
From: Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia
After a median follow-up of 9.3 months (range: 0.2–26.1 months) median OS of the entire cohort (n = 188) was 21 months and estimated 2-year OS was 35%. OS for the entire cohort was calculated as the time from the first day of treatment with CPX-351 to death from any cause or last follow-up in survivors.
